Поддерживающая терапия при раке яичников
- Авторы: Покатаев ИА1, Тюляндин СА1
-
Учреждения:
- ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России
- Выпуск: Том 18, № 2 (2016)
- Страницы: 81-87
- Раздел: Статьи
- URL: https://journals.rcsi.science/1815-1434/article/view/27098
- ID: 27098
Цитировать
Полный текст
Аннотация
Хирургический этап является основным в лечении пациенток, страдающих раком яичников. При этом успехи терапии данной патологии в последние годы связаны прежде всего с более эффективным лекарственным лечением. Новые лекарственные препараты и режимы химиотерапии существенно изменили принципы лекарственного лечения этого заболевания, позволив внедрить поддерживающий этап терапии, который еще 5 лет назад считался нецелесообразным ввиду ограниченной эффективности и высокой токсичности.
Полный текст
Открыть статью на сайте журналаОб авторах
И А Покатаев
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России
Email: Pokia@mail.ru
канд. мед. наук, врач-онколог ФГБУ РОНЦ им. Н.Н.Блохина 115478, Россия, Москва, Каширское ш., д. 23
С А Тюляндин
ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава Россиид-р мед. наук, проф., зав. отд-нием клинической фармакологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Россия, Москва, Каширское ш., д. 23
Список литературы
- Тюляндин С.А., Деньгина Н.В., Коломиец Л.А. и др. Практические рекомендации по лекарственному лечению рака яичников. Злокачественные опухоли. 2015; 4 (Спецвыпуск): 116-26.
- Markman M, Rothman R, Hakes T et al. Second - line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9 (3): 389-93.
- Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59 (4): 650-3.
- Gore M.E, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36 (2): 207-11.
- Тюляндина А.С. Лекарственное лечение рака яичников. Практич. онкология. 2014; 15 (4): 168-75.
- Bookman M.A, Brady M.F, Mc Guire et al. Evaluation of new platinum - based treatment regimens in advanced - stage ovarian cancer: A phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 2009; 27: 1419-25.
- Pignata S, Scambia G, Ferrandina G et al. Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First - Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. J Clin Oncol 2011; 29: 1-11.
- Pignata S, Scambia G, Raspagliesi F et al. The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum - free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum - based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG. Clin Oncol 2016; 34 (Suppl.; abstr. 5505).
- Katz M.E, Schwartz P.E, Kapp D.S et al. Epithelial carcinoma of the ovary: current strategies. Ann Int Med 1981; 95: 98-111.
- Young P.C, Chabner B.A, Hubbard S.P et al. Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (LPAM) versus combination chemotherapy. New Engl J Med 1978; 299: 1261-6.
- Greene M.H, Boice J.D Jr., Greer B.E et al. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized trials. New Engl J Med 1982; 307: 1416-21.
- Travis L.B, Curtin R.E, Boice J.D.Jr et al. Second malignant neoplasms among long - term survivors of ovarian cancer. Cancer Res 1996; 56: 1564-70.
- Lambert H.E, Rustin G.J, Gregory W.M et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997; 8: 327-33.
- Bertelsen K, Jakobsen A, Stroyer J et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993; 49: 30-6.
- Hakes T.B, Chalas E, Hoskins W.J et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 45: 284-9.
- Markman M. Maintenance chemotherapy in the management of epithelial ovarian cancer. Cancer Metastasis Rev 2015; 34 (1): 11-7.
- Markman M, Liu P.Y, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel - based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-5.
- Mannel R.S, Brady M.F, Kohn E.C et al. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low - dose paclitaxel in patients with early - stage ovarian carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2011; 122 (1): 89-94.
- Bocci G, Di Paolo A, Danesi R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis 2013; 16: 481-92.
- Oza A.M, Cook A.D, Pfisterer J et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015; 16: 928-36.
- Robert A. Burger, M.D, Mark F et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med 2011; 365: 2473-83.
- Du Bois A, Floquet A, Kim J.W et al. Randomized, double - blind, phase III trial of pazopanib versus placebo in women who have progressed after first - line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: results of an international Intergroup trial (AGO-OVAR 16). J Clin Oncol 2013; 31 (Suppl.; LBA 5503).
- Du Bois A, Kristensen G, Ray-Coquard I et al. AGO-OVAR 12: a randomized placebo - controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Abstracts from the 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), 19-22 October 2013, Liverpool, UK. Int J Gynecol Cancer 2013; 23 (8 Suppl. 1).
- Yokoyama Y, Mizunuma H. Recurrent epithelial ovarian cancer and hormone therapy. World J Clin Cases 2013; 1 (6): 187-90.
- Gershenson D, Bodurka D, Coleman R et al. Hormonal maintenance therapy for women with low grade serous carcinoma of the ovary or peritoneum. J Clin Oncol 2016; 34 (Suppl.; abstr. 5502).
- Munstedt K, Steen J, Knauf A.G et al. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 2000; 89: 1783-91.
- Berek J, Taylor P, Mc Guire W et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009; 27: 418-25.
- Sabbatini P, Harter P, Scambia G et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO - The MIMOSA Study. J Clin Oncol 2013; 31: 1554-61.
- Vergote I.B, Jimeno A, Joly F et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first - line platin - based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer - Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol 2014; 32: 320-6.
- Любченко Л.Н., Батенева Е.И., Абрамов И.С. и др. Наследственный рак молочной железы и яичников. Злокачественные опухоли. 2013; 2: 53-61.
- Тюляндина А.С. Настоящее и будущее таргетной терапии в первой линии лечения рака яичников. Фарматека. 2013; 8: 39-42.
- Soegaard M, Kjaer S.K, Cox M et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population - based series of ovarian cancer cases from Denmark. Clin Cancer Res 2008; 14 (12): 3761-7.
- Aghajanian C, Goff B, Nycum L.R et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum - sensitive recurrent ovarian cancer. Gynecol Oncol 2015; 139 (1): 10-6.
- Pujade-Lauraine E, Hilpert F Weber B et al. Bevacizumab Combined With Chemotherapy for Platinum - Resistant Recurrent Ovarian Cancer: The AURELIA Open - Label Randomized Phase III Trial. J Clin Oncol 2014; 32: 4014-25.
- Ledermann J.A, Embleton A.C, Raja F et al. Cediranib in patients with relapsed platinum - sensitive ovarian cancer (ICON6): a randomised, double - blind, placebo - controlled phase 3 trial. Lancet 2016; 387 (10023): 1066-74.
- Monk B.J, Poveda A, Vergote I et al. Anti - angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double - blind, placebo - controlledphase 3 trial. Lancet Oncol 2014; 15 (8): 799-808.
- Committee for Medicinal Products for Human Use. Lynparza (olaparib). 23 October 2014. EMA/CHMP/632090/2014. http://www.ema. europa.eu/ema/index.jsp ?curl= pages/medicines/human/medicines/003726/smops/Positive/human_smop_000744.jsp&mid=WC0b01ac058001d127
- Ledermann J, Harter P, Gourley C et al. Olaparib Maintenance Therapy in Platinum - Sensitive Relapsed Ovarian Cancer. N Engl J Med 2012; 366: 1382-92.
- Ledermann J, Harter P, Gourley C et al. Overall survival (OS) in patients (pts) with platinum - sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. J Clin Oncol 2016; 34 (Suppl.; abstr. 5501).
- Matulonis U, Harter P, Gourley C et al. Olaparib Maintenance Therapy in Patients With Platinum - Sensitive, Relapsed Serous Ovarian Cancer and a BRCA Mutation: Overall Survival Adjusted for Postprogression Poly(Adenosine Diphosphate Ribose) Polymerase Inhibitor Therapy. Cancer. In print.
- Hall G.D, Brown J.M, Coleman R.E et al. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire Gynecology Group randomized phase III study. Brit J Cancer 2004; 91: 621-6.
- Alberts D.S, Hannigan E.V, Liu P.Y et al. Randomized trial of adjuvant intraperitoneal alpha - interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecol Oncol 2006; 100: 133-8.
- The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian Carcinoma. Nature 2011; 474: 609-15.